Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of “Buy” from Brokerages

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) have been assigned a consensus rating of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $12.20.

RANI has been the subject of a number of research analyst reports. Canaccord Genuity Group decreased their target price on Rani Therapeutics from $21.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 27th. BTIG Research upped their price objective on Rani Therapeutics from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright lifted their price objective on Rani Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Rani Therapeutics in a research report on Tuesday, February 6th.

Rani Therapeutics Trading Down 5.2 %

NASDAQ RANI traded down $0.37 during trading hours on Thursday, hitting $6.78. The company’s stock had a trading volume of 223,650 shares, compared to its average volume of 128,113. The stock has a fifty day moving average of $4.73 and a 200 day moving average of $3.53. Rani Therapeutics has a twelve month low of $1.82 and a twelve month high of $8.75. The firm has a market capitalization of $340.08 million, a P/E ratio of -5.28 and a beta of 0.33. The company has a quick ratio of 6.36, a current ratio of 6.36 and a debt-to-equity ratio of 0.96.

Rani Therapeutics (NASDAQ:RANI) last posted its earnings results on Wednesday, March 20th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.04. Equities research analysts forecast that Rani Therapeutics will post -0.94 earnings per share for the current fiscal year.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.